Bladder S1937
Study #S1937A Phase III Randomized Trial of Eribulin (NSC#707389) with or without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti-PD1/PDL1 Therapy
Back To Clinical Trials NCI Database Entry